• Welcome, Guest. Please login or register.
    March 23, 2018, 12:17:36 AM

  • Login with username, password and session length

Sajid's dove

Tell everyone they can now find this site by typing this into their browser:


Click to visit us on Facebook

If you have any problems registering or signing in, please send an email to: andy@thalpal.com
Please do not send questions about thalassemia to this address.


Thalassemia Patients and Friends and thalpal Ā© A. Battaglia 2017

54435 Posts in 5743 Topics by 5906 Members
Latest Member: Ursula

Forum Tip: 
Put your birthdate in your profile, under "Forum Profile Information," and it will automatically come up on our calendar.
« previous next »
Pages: 1 Go Down Print
Author Topic: definite alternative to hydroxyurea  (Read 358 times)
Junior Member
Offline Offline

Posts: 125

« on: November 26, 2017, 08:57:09 AM »

I ran across this in my files and wonder why I never posted it.

Leuk Lymphoma. 2003 Sep;44(9):1483-8.
Treatment of polycythemia vera and essential thrombocythemia: the role of pipobroman.
Passamonti F1, Lazzarino M.
Author information
Pipobroman (PB) is a neutral amide of piperazine with a chemical structure close to that of alkylating agents, although the exact mechanism of action of PB has not been demonstrated. PB has well documented clinical activity in polycythemia vera (PV) and essential thrombocythemia (ET). Recent long-term follow-up studies on PV and ET patients receiving PB have facilitated the definition of the risk of late transformation into myelofibrosis with myeloid metaplasia (MMM) or acute leukemia (AL). This report gives an overview of the treatment with PB in patients with PV and ET focusing on clinical activity, administration dose and schedule, toxicity, impact on short- and long-term complications. From our experience and from the data reported in the literature the high clinical activity of PB in both PVand ET becomes evident. This drug allows, within 3 months, to attain a response in more than 90% of patients, without clinically relevant toxicities. The 10-years risk of thrombosis of patients treated with PB is about 15%, similar to that registered with hydroxyurea, the most widely used agent in PVand ET. The antiproliferative activity of PB on bone marrow megakaryocytes seems of particular value in lowering the occurrence of post-PV and post-ET MMM, whose risk (< 4% at 10 years) is the lowest registered with available treatments. The 10-year risk of acute leukemia with PB is 5% in PVand 3% in ET, which is only slightly higher than that expected as a natural evolution of the disease. In conclusion, the use of PB is a definite alternative to hydroxyurea in patients with PV and ET at high risk of thrombosis.
PMID: 14565648 DOI: 10.3109/10428190309178768
Pages: 1 Go Up Print 
« previous next »
Jump to:  

Powered by MySQL Powered by PHP Powered by SMF 1.1.21 | SMF © 2015, Simple Machines Valid XHTML 1.0! Valid CSS!